2026 ACCP Virtual Journal Club Webinar: Utilization of Proteomic Measures for Early Detection of Drug Benefits and Adverse Effects

Live Session: Wednesday, October 7^th, 2026, from 12:00 to 1:00 PM ET

On Demand: October 7^th, 2026 to October 7^th, 2029

Why is this webinar important to your practice? 

Learners that complete this webinar will be able to describe how proteomic biomarkers may be used to evaluate drug benefits and adverse effects during clinical development. This activity will examine evidence from multiple clinical trials and drug classes demonstrating the potential of proteomic measures to detect treatment effects earlier and with fewer participants than traditional clinical outcome studies and discuss their potential application in clinical research and drug development.

Target Audience:

Interprofessional team of Physicians, Pharmacists, PhDs and other health care professionals interested in proteomic biomarkers in drug development.

Learning Objectives

After completing this activity, the learner will be able to:

1. Describe the challenges associated with traditional drug development and explain how proteomic biomarkers may enable earlier detection of drug efficacy and safety signals;
2. Explain the principles of proteomic profiling and the development of tests for cardiovascular, renal, and cardiometabolic risk assessment;
3. Identify evidence supporting the use of proteomic surrogate endpoints to predict therapeutic benefits and adverse effects across multiple drug classes.